John F. Seymour, MBBS, PhD, on CLL: Results From the MURANO Study

2017 ASH Annual Meeting
Tweet this page

John F. Seymour, MBBS, PhD, of the Peter MacCallum Cancer Centre, discusses an interim analysis of venetoclax plus rituximab vs bendamustine plus rituximab in patients with relapsed/refractory chronic lymphocytic leukemia (Abstract LBA-2).

Advertisement

Advertisement



Advertisement